Marc Levivier

Marc Levivier

Auto-generated profile, based on publicly available information

Marc Levivier

Department of Clinical Neurosciences, Neurosurgery Service and Gamma Knife Center, Centre Hospitalier Universitaire Vaudois (CHUV), Lausanne, Switzerland

Research Focus & Metrics

Academic Career Length

42Years (1985-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 July 1999 in Movement Disorders
Verified
Journal Article
Closed access
PDF file
GDGilles-Louis Defer
Gilles-Louis Defer
HWHakan Widner
Hakan Widner
MLMarc Levivier
Marc Levivier
RMRose‐Marie Marié
Rose‐Marie Marié
PRPhilippe Rémy
Philippe Rémy

1 July 2003 in The Lancet Neurology
Verified
Journal Article
Closed access
ABAnders Björklund
Anders Björklund
SDStephen B Dunnett
Stephen B Dunnett
PBPatrik Brundin
Patrik Brundin
ASA Jon Stoessl
A Jon Stoessl
CFCurt R Freed
Curt R Freed
RBRoger Barker
Roger Barker

1 September 2004 in International Journal of Radiation Oncology - Biology - Physics (IJROBP)
Verified
Journal Article
Closed access
JLJosé Lorenzoni
José Lorenzoni
DDDaniel Devriendt
Daniel Devriendt
NMNicolas Massager
Nicolas Massager
PDPhillippe David
Phillippe David
SRSalvador Ruíz
Salvador Ruíz
MLMarc Levivier
Marc Levivier

30 January 2014 in Intensive Care Medicine
Verified
Journal Article
Closed access
PDF file
PBPierre Bouzat
Pierre Bouzat
NSNathalie Sala
Nathalie Sala
TSTamarah Suys
Tamarah Suys
JZJean-Baptiste Zerlauth
Jean-Baptiste Zerlauth
Pedro Marques-VidalPedro Marques-Vidal
Pedro Marques-Vidal
MOMauro Oddo
Mauro Oddo

1 April 2016 in Journal of Neurosurgery
Verified
Journal Article
Open access
JRJean Régis
Jean Régis
CTConstantin Tuleasca
Constantin Tuleasca
NRNoémie Resseguier
Noémie Resseguier
RCRomain Carron
Romain Carron
ADAnne Donnet
Anne Donnet
MLMarc Levivier
Marc Levivier
OBJECT: Gamma Knife surgery (GKS) is one of the surgical alternatives for the treatment of drug-resistant trigeminal neuralgia (TN). This study aims to evaluate the safety and efficacy of GKS in a large population of patients with TN with very long-term clinical follow-up. METHODS: Between July 1992 and November 2010, 737 patients presenting with TN were treated using GKS. Data were collected prospectively and were further retrospectively evaluated at Timone University Hospital. The frequency and severity of pain, as well as trigeminal nerve function, were evaluated before GKS and regularly thereafter. Radiosurgery using the Gamma Knife (model B, C, 4C, or Perfexion) was performed with the help of both MR and CT targeting. A single 4-mm isocenter was positioned in the cisternal portion of the trigeminal nerve at a median distance of 7.6 mm (range 4–14 mm) anterior to the emergence of the nerve (retrogasserian target). A median maximum dose of 85 Gy (range 70–90 Gy) was prescribed. RESULTS: The safety and efficacy are reported for 497 patients with medically refractory classical TN who were never previously treated by GKS and had a follow-up of at least 1 year. The median age in this series was 68.3 years (range 28.1–93.2 years). The median follow-up period was 43.8 months (range 12–174.4 months). Overall, 456 patients (91.75%) were initially pain free in a median time of 10 days (range 1–180 days). Their actuarial probabilities of remaining pain free without medication at 3, 5, 7, and 10 years were 71.8%, 64.9%, 59.7%, and 45.3%, respectively. One hundred fifty-seven patients (34.4%) who were initially pain free experienced at least 1 recurrence, with a median delay of onset of 24 months (range 0.6–150.1 months). However, the actuarial rate of maintaining pain relief without further surgery was 67.8% at 10 years. The hypesthesia actuarial rate at 5 years was 20.4% and at 7 years reached 21.1%, but remained stable until 14 years with a median delay of onset of 12 months (range 1–65 months). Very bothersome facial hypesthesia was reported in only 3 patients (0.6%). CONCLUSIONS: Retrogasserian GKS proved to be safe and effective in the long term and in a very large number of patients. Even if the probability of long-lasting effects may be modest compared with microvascular decompression, the rarity of complications prompts discussion of using GKS as the pragmatic surgical first- or second-intention alternative for classical TN. However, a randomized trial, or at least a case-matched control study, would be required to compare with microvascular decompression.

10 February 2004 in The Journal of Gene Medicine
Verified
Journal Article
Closed access
PDF file
LTLiliane Tenenbaum
Liliane Tenenbaum
ACA. Chtarto
A. Chtarto
ELE. Lehtonen
E. Lehtonen
TVT. Velu
T. Velu
JBJ. Brotchi
J. Brotchi
MLM. Levivier
M. Levivier